Pimavanserin tartrate

After scoring the first FDA approval for a Rett syndrome treatment last year, Acadia Pharmaceuticals has now sold the rare paediatric disease priority review voucher it gained along with the greenlight. Daybue (trofinetide), an analogue of the neuropeptide IGF-1, was cleared to treat adult and paediatric patients two years and older with the rare genetic disorder.Acadia said the voucher sold for $150 million, but did not disclose the buyer. The drug developer will only profit $100 million off the sale, however, as Neuren Pharmaceuticals — from whom Acadia gained North American rights for Daybue — is entitled to one-third, or $50 million, of the proceeds. The funds will be invested into Acadia's commercial efforts, as well as its R&D work in central nervous system disorders and rare diseases.In addition to Daybue, the firm markets one other drug — Nuplazid (pimavanserin) for Parkinson’s disease psychosis.The company's pipeline features three clinical assets, and several undisclosed programmes in preclinical development. The most advanced, ACP-101, is in Phase III testing for hyperphagia in Prader-Willi syndrome. The next, ACP-204, is in Phase II testing for Alzheimer's disease psychosis, and Acadia has exclusive, worldwide rights to Phase I-stage candidate ACP-2591 for Rett and fragile X syndromes from Neuren. In March, Acadia's attempt to expand Nuplazid's label beyond psychosis and into schizophrenia crumbled after the inverse serotonin 5-HT2A receptor agonist failed a Phase III study.

Acadia Pharmaceuticals agreed to sell a priority review voucher to an undisclosed buyer for $150 million, a price tag on the high end for the coveted passes that speed up Food and Drug Administration reviews of new medicines.The company won the voucher in March 2023, along with FDA approval of its Daybue treatment for a rare pediatric disease. The transaction will leave Acadia with $100 million after sharing proceeds with Neuren Pharmaceuticals, the company said Tuesday. Acadia licensed Daybue from Neuren in 2018.Prices for the vouchers have often hovered between $100 million and $110 million in recent years in deals by companies including Bluebird bio, Novo Nordisk and Sarepta Therapeutics. This year has seen a $103 million sale by Valnevain February, $105 million by X4 Pharmaceuticals in May, $108 million by Day One Biopharmaceuticalsin May and $158 million by Ipsenin August.The move is a nice incremental win, RBC Capital Markets analyst Gregory Renza wrote in a note to clients. Acadias patience in waiting for a high bid paid off as the scarcity value is perhaps more appreciated by the market, Renza wrote. He noted that the FDAs planned sunsettingof the rare pediatric disease voucher program is likely pushing values higher.Acadia said it will use the proceeds to support commercial operations, spur future business development and fund rare disease and central nervous system research. In addition to Daybue, Acadia sells a drug called Nuplazid for hallucinations and delusions associated with Parkinsons disease psychosis.Daybue is used to treat Rett syndrome, a rare neurological disorder that usually strikes infants between the ages of six and 18 months, causing their development to regress. Daybue had sales of $85 million in the second quarter. '